159 related articles for article (PubMed ID: 1794269)
1. Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
Della Casa L; del Rio G; Glaser B; Cerasi E
Diabetes Res Clin Pract; 1991; 14 Suppl 2():S69-78. PubMed ID: 1794269
[TBL] [Abstract][Full Text] [Related]
2. Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia.
Della Casa L; del Rio G; Glaser B; Cerasi E
Am J Med; 1991 Jun; 90(6A):37S-45S. PubMed ID: 1872303
[TBL] [Abstract][Full Text] [Related]
3. Insulin resistance, insulin deficiency, and non-insulin-dependent diabetes mellitus.
Cerasi E
Diabetes Res Clin Pract; 1991; 14 Suppl 2():S37-45. PubMed ID: 1794264
[TBL] [Abstract][Full Text] [Related]
4. Improvement in glucose-induced insulin secretion in diabetic rats after long-term gliclazide treatment: a comparative study using different models of non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin.
Portha B; Serradas P
Am J Med; 1991 Jun; 90(6A):15S-21S. PubMed ID: 1831320
[TBL] [Abstract][Full Text] [Related]
5. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
Pontiroli AE; Pacchioni M; Piatti PM; Cassisa C; Camisasca R; Pozza G
J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830
[TBL] [Abstract][Full Text] [Related]
6. Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control.
Vestergaard H; Lund S; Bjørbaek C; Pedersen O
Diabetologia; 1995 Oct; 38(10):1230-8. PubMed ID: 8690177
[TBL] [Abstract][Full Text] [Related]
7. The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
Matthews DR; Boland O
Metabolism; 1997 Dec; 46(12 Suppl 1):5-9. PubMed ID: 9439551
[TBL] [Abstract][Full Text] [Related]
8. Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM).
Wajchenberg BL; Santomauro AT; Porrelli RN
Diabetes Res Clin Pract; 1993 May; 20(2):147-54. PubMed ID: 8375268
[TBL] [Abstract][Full Text] [Related]
9. Influence of gliclazide on glucose-stimulated insulin release in man.
van Haeften TW; Veneman TF; Gerich JE; van der Veen EA
Metabolism; 1991 Jul; 40(7):751-5. PubMed ID: 1870430
[TBL] [Abstract][Full Text] [Related]
10. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
Rachman J; Levy JC; Barrow BA; Manley SE; Turner RC
Diabetes; 1997 Oct; 46(10):1557-62. PubMed ID: 9313749
[TBL] [Abstract][Full Text] [Related]
11. Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects.
Ward G; Harrison LC; Proietto J; Aitken P; Nankervis A
Diabetes; 1985 Mar; 34(3):241-5. PubMed ID: 3882491
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of ambient blood glucose level and degree of obesity on basal serum C-peptide level and the C-peptide response to glucose and glucagon in non-insulin-dependent diabetes mellitus.
Park SW; Ihm SH; Yoo HJ; Park JY; Lee KU
Diabetes Res Clin Pract; 1997 Sep; 37(3):165-71. PubMed ID: 9306037
[TBL] [Abstract][Full Text] [Related]
13. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
14. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
Hosker JP; Rudenski AS; Burnett MA; Matthews DR; Turner RC
Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
[TBL] [Abstract][Full Text] [Related]
15. Comparison of beta-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats.
Kawai K; Suzuki S; Murayama Y; Watanabe Y; Yamashita K
Diabetes Res Clin Pract; 1991 Jul; 12(3):163-72. PubMed ID: 1832376
[TBL] [Abstract][Full Text] [Related]
16. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
Gutniak M; Orskov C; Holst JJ; Ahrén B; Efendic S
N Engl J Med; 1992 May; 326(20):1316-22. PubMed ID: 1348845
[TBL] [Abstract][Full Text] [Related]
17. The physiological action of gliclazide: beta-cell function and insulin resistance.
Matthews DR; Hosker JP; Stratton I
Diabetes Res Clin Pract; 1991; 14 Suppl 2():S53-9. PubMed ID: 1794266
[TBL] [Abstract][Full Text] [Related]
18. Changes in glucose disposal and cellular insulin binding in obese black Southern African patients with type 2 diabetes mellitus before and after sulphonylurea therapy.
Wing JR; Panz VR; Joffe BI; Seftel HC
Diabet Med; 1993; 10(1):50-5. PubMed ID: 8435988
[TBL] [Abstract][Full Text] [Related]
19. Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.
Ligtenberg JJ; Reitsma WD; van Haeften TW
Horm Metab Res; 2001 Jun; 33(6):361-4. PubMed ID: 11456286
[TBL] [Abstract][Full Text] [Related]
20. Gliclazide in the treatment of obese non-insulin dependent diabetic patients.
Seshiah V; Venkataraman S; Suresh K
J Assoc Physicians India; 1993 Jun; 41(6):367-8. PubMed ID: 8005974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
